Extended antidepressant maintenance and discontinuation syndromes
dc.contributor.author | Maixner, Susan M. | en_US |
dc.contributor.author | Greden, John F. | en_US |
dc.date.accessioned | 2006-04-19T14:17:17Z | |
dc.date.available | 2006-04-19T14:17:17Z | |
dc.date.issued | 1998 | en_US |
dc.identifier.citation | Maixner, Susan M.; Greden, John F. (1998)."Extended antidepressant maintenance and discontinuation syndromes." Depression and Anxiety 8(S1): 43-53. <http://hdl.handle.net/2027.42/35217> | en_US |
dc.identifier.issn | 1091-4269 | en_US |
dc.identifier.issn | 1520-6394 | en_US |
dc.identifier.uri | https://hdl.handle.net/2027.42/35217 | |
dc.identifier.uri | http://www.ncbi.nlm.nih.gov/sites/entrez?cmd=retrieve&db=pubmed&list_uids=9809213&dopt=citation | en_US |
dc.description.abstract | Unipolar and bipolar depression are episodic, recurrent illnesses for the majority of patients. Because each episode engenders considerable costs for patients, families, and society, prevention of recurrences has high priority. Numerous studies demonstrate that maintenance antidepressants or mood stabilizing medications are efficacious in preventing recurrences. A review of maintenance studies supports the view that all antidepressants perform significantly better than placebo in preventing recurrences of depression—with the stipulation that full antidepressant doses be employed. Earliest studies, conducted two decades ago, evaluated tricyclics (TCAs), heterocyclics, and lithium, while recent studies have focused on selective serotonin reuptake inhibitors (SSRIs). Compliance is essential. Strategies for enhancing compliance include selection of medications with reported safety and few side effects, education of patients and families, referral to patient advocacy groups, and use of new technological compliance aids. Preliminary data suggest that SSRIs are better tolerated than TCAs; fewer patients discontinue these agents due to side effects. Selection criteria for maintenance treatment have not been well determined, but three or more prior episodes is recognized as a relatively strong indicator. Other clinical or genetic criteria have also been suggested. For various reasons, patients may discontinue medications, and when this happens withdrawal phenomena may occur. Withdrawal effects are well documented for all antidepressants and can be profound with TCAs. After stopping some SSRIs, a few withdrawal symptoms may have similarities with those following discontinuation of TCAs, but unique “CNS-like” effects are frequently described, including brief recurrent episodes of dizziness, lightheadedness, vertigo, electric shock-like sensations, and gait instability. These appear to be half-life dependent, with agents with shorter half-lives having more discontinuation symptoms. If antidepressant medications must be discontinued, a gradual taper is preferable, perhaps extending three to six months or longer to prevent discontinuation effects, enable adaptation at the receptor level and allow earlier recognition and treatment of recurrent depressive symptoms. Depression and Anxiety, Volume 8, Supplement 1:43–53, 1998. © 1998 Wiley-Liss, Inc. | en_US |
dc.format.extent | 75660 bytes | |
dc.format.extent | 3118 bytes | |
dc.format.mimetype | application/pdf | |
dc.format.mimetype | text/plain | |
dc.language.iso | en_US | |
dc.publisher | John Wiley & Sons, Inc. | en_US |
dc.subject.other | Life and Medical Sciences | en_US |
dc.subject.other | Neuroscience, Neurology and Psychiatry | en_US |
dc.title | Extended antidepressant maintenance and discontinuation syndromes | en_US |
dc.type | Article | en_US |
dc.rights.robots | IndexNoFollow | en_US |
dc.subject.hlbsecondlevel | Psychiatry | en_US |
dc.subject.hlbsecondlevel | Psychology | en_US |
dc.subject.hlbtoplevel | Health Sciences | en_US |
dc.subject.hlbtoplevel | Social Sciences | en_US |
dc.description.peerreviewed | Peer Reviewed | en_US |
dc.contributor.affiliationum | Department of Psychiatry, University of Michigan Medical Center, Ann Arbor, Michigan ; Department of Psychiatry, University of Michigan Medical Center, Ann Arbor, MI 48109 | en_US |
dc.contributor.affiliationum | Department of Psychiatry, University of Michigan Medical Center, Ann Arbor, Michigan ; Mental Health Research Institute, University of Michigan Medical Center, Ann Arbor, Michigan | en_US |
dc.identifier.pmid | 9809213 | en_US |
dc.description.bitstreamurl | http://deepblue.lib.umich.edu/bitstream/2027.42/35217/1/7_ftp.pdf | en_US |
dc.identifier.doi | http://dx.doi.org/10.1002/(SICI)1520-6394(1998)8:1+<43::AID-DA7>3.0.CO;2-C | en_US |
dc.identifier.source | Depression and Anxiety | en_US |
dc.owningcollname | Interdisciplinary and Peer-Reviewed |
Files in this item
Remediation of Harmful Language
The University of Michigan Library aims to describe library materials in a way that respects the people and communities who create, use, and are represented in our collections. Report harmful or offensive language in catalog records, finding aids, or elsewhere in our collections anonymously through our metadata feedback form. More information at Remediation of Harmful Language.
Accessibility
If you are unable to use this file in its current format, please select the Contact Us link and we can modify it to make it more accessible to you.